
Schering-Plough and Organon merger finalized
Schering-Plough/Organon merger passes antitrust scrutiny and is completed
The Federal Trade Commission has cleared Schering-Plough's acquisition of Organon BioSciences N.V. from Akzo Nobel N.V. with no requirement for any divestitures in human health products. So Schering-Plough announced the merger is now complete. According to Schering-Plough's CEO Fred Hassan, Organon brings to the table two important pharmaceutical franchises, women's health and central nervous system products. In addition, it has several promising phase III compounds in development.
To go to the Drug Topics homepage,
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.


























































































































































